Abstract

Table S1 Clinical and Laboratory Characteristics of the Patients. Table S2 Agreement between three rapid tests and MGIT for detection of resistance for isoniazid (INH), rifampin (RIF), amikacin (AMK), capreomycin (CAP), kanamycin (KAN), moxifloxacin (MOX), and ofloxacin (OFX). Table S3 Proportion of total assay runs that produced interpretable results from three diagnostic platforms (LPA, PSQ and MODS) with the ability to detect resistance to isoniazid (INH), rifampin (RIF), amikacin (AMK), capreomycin (CAP), kanamycin (KAN), moxifloxacin (MOX), and ofloxacin (OFX). (DOCX 35 kb

    Similar works

    Full text

    thumbnail-image

    Available Versions